American Exceptionalism Acquisition Corp. A Liquidation Value

American Exceptionalism Acquisition Corp. A (AEXA) is a blank check Cayman Islands SPAC incorporated July 11, 2025 and listed on NYSE. The 10-K covers the period from inception through December 31, 2025. Under a liquidation lens, the balance sheet is structurally bifurcated: the dominant asset is $348.4M of marketable securities held in a grantor trust, which is contractually ring-fenced for redemption by public shareholders at approximately $10.10 per share. Under liquidation, that asset recovers at effectively 100% (money market funds invested in U.S. Treasuries, Level 1 fair value), but the corresponding redemption obligation to 34.5M public Class A shareholders absorbs essentially all of it. Recovery to the residual equity claimants — sponsor and founder shareholders — is therefore driven entirely by assets outside the trust.

Outside-trust assets total $736K current ($516K cash, $212K prepaid, $8K due from sponsor) and $146K long-term prepaid insurance. Applying standard liquidation haircuts, recoverable outside-trust value is approximately $516K cash (100%) + $0 for prepaids and insurance (no liquidation value) = roughly $516K gross. Against this, current liabilities stand at $101K (accrued expenses $16K + accrued offering costs $85K). However, two large non-current liabilities — advisory fee payable $10.35M and deferred underwriting fee payable $10.35M, totaling $20.7M — sit at face value in the liability stack. These are contingent on a business combination closing, but are recorded as unconditional obligations on the balance sheet per the termination clause in the advisory agreement. On a pure face-value liquidation basis, total liabilities of $20.8M vastly exceed outside-trust assets of under $1M, producing negative recovery for sponsor equity of approximately negative $20.3M. This matches the reported shareholders' deficit of negative $19.9M.

Relative to the prior 10-Q (September 30, 2025), the trust account grew from $345.0M to $348.4M reflecting $3.4M of interest earned. Outside-trust cash declined from $882K to $516K as operating expenses were paid. The advisory fee payable was present at Q3 ($10.35M) and remains unchanged. The going-concern qualification from the auditor (WithumSmith+Brown) is unchanged from the Q3 period. No business combination target has been identified. The completion window runs to September 29, 2027 absent extension. Sponsor's total invested capital is $1.775M ($25K founder shares + $1.75M private placement); no promissory note or working capital loans are outstanding at December 31, 2025. Filing discusses the $10.35M advisory fee and $10.35M deferred underwriting discount in MD&A and Note 6 as contingent but recorded; both are tagged in XBRL as company-specific extension elements.